Cancer BiologybioRxivPreprint
KIF18A Inhibition as a Therapeutic Strategy in Cancers with Rb Pathway Inactivation
Celia Andreu, Arshi Arora, Song Chen…·Samuel F. W. Bakhoum
This paper identifies p16INK4a expression as a predictive biomarker for KIF18A inhibitor response in cancers with Rb pathway inactivation, showing higher response rates and longer progression-free survival in p16INK4a-high tumors.
DOI 10.64898/2026.04.14.718587